25 January 2017 in Haematologica
Minimal residual disease prior to allogeneic hematopoietic cell transplantation has been associated with increased risk of relapse and death in patients with acute myeloid leukemia, but detection methodologies and results vary widely. We performed a systematic review and meta-analysis evaluating the prognostic role of minimal residual disease detected by polymerase chain reaction or multiparametric flow cytometry before transplant. We identified 19 articles published between January 2005 and June 2016 and extracted hazard ratios for leukemia-free survival, overall survival, and cumulative incidences of relapse and non-relapse mortality. Pre-transplant minimal residual disease was associated with worse leukemia-free survival (hazard ratio=2.76 [1.90–4.00]), overall survival (hazard ratio=2.36 [1.73–3.22]), and cumulative incidence of relapse (hazard ratio=3.65 [2.53–5.27]), but not non-relapse mortality (hazard ratio=1.12 [0.81–1.55]). These associations held regardless of detection method, conditioning intensity, and patient age. Adverse cytogenetics was not an independent risk factor for death or relapse. There was more heterogeneity among studies using flow cytometry-based than WT1 polymerase chain reaction-based detection (I2=75.1% vs. <0.1% for leukemia-free survival, 67.8% vs. <0.1% for overall survival, and 22.1% vs. <0.1% for cumulative incidence of relapse). These results demonstrate a strong relationship between pre-transplant minimal residual disease and post-transplant relapse and survival. Outcome heterogeneity among studies using flow-based methods may underscore site-specific methodological differences or differences in test performance and interpretation.
1 January 2018 in Blood Reviews
7 September 2017 in Cancer
BACKGROUND: Although outcomes for acute myeloid leukemia (AML) have improved over time, they remain poor overall, and toxicity from both the disease and its treatment can affect quality of life (QOL). One barrier to including QOL endpoints in clinical trials is the lack of a disease‐specific QOL instrument that can efficiently capture the major QOL deficits in this population.METHODS: A cross‐sectional study was performed to elicit concepts for inclusion in a new AML‐specific QOL instrument called the AML‐QOL. Eighty‐two patients at various stages of disease were interviewed about sources of support (positive concepts) and problems and symptoms (negative concepts) experienced over the past week, and they were asked to grade how much each affected their QOL. In addition, patients were asked to complete 2 validated instruments: the Functional Assessment of Cancer Therapy with the leukemia and transplant modules and the 29‐item Patient‐Reported Outcomes Measurement Information System questionnaire.RESULTS: With data from the open‐ended and questionnaire‐based portions of the interview, 7 positive concepts and 64 negative concepts were elicited. From these, 5 positive concepts and 21 negative concepts were selected for inclusion in the preliminary AML‐QOL on the basis of concept prevalence and the impact on QOL.CONCLUSIONS: These concepts will form the basis of a new QOL instrument specific to AML. Cancer 2018;124:145‐52. © 2017 American Cancer Society.
25 July 2016 in Expert Review of Hematology
(2016). Measuring quality of life in acute myeloid leukemia: limitations and future directions. Expert Review of Hematology: Vol. 9, No. 9, pp. 821-823.
1 February 2013 in The Journal of Clinical Endocrinology & Metabolism
8 April 2015 in British Journal of Haematology